• Home
• About
the Chapter
• 
Board
of Directors
• Coding
Information
• CHF
Support Group
• Job
Board
• Legislative
• Meetings
& Events
• News
& Publications
• On-Line
Resources
• Sponsorship
Read the full diabetes module for cardiology
Evidence-based
drivers
Driver
One
Reducing blood glucose levels and HbA1c levels reduces the
risk of diabetic complications. Intensive
therapy has been shown to be superior to conventional therapy in terms of
reducing glycemia and diabetic complications.
Driver
Two
When monotherapy with an oral agent is no longer adequate, combination
therapy with 2 or more oral agents has been shown to significantly improve
glycemic control.
Driver
Three
When oral monotherapy or combination oral therapy is no longer adequate,
insulin can be added to the regimen to significantly improve glycemic
control.
Driver
Four
Benefits of insulin therapy, such as improved outcomes and glycemic
control, outweigh risks such as the potential for inducing hypoglycemia.
Driver
Five
Type 2 diabetes mellitus is a disease consisting of two components
insulin resistance and insulin deficiency.
This
Scientific Evidence Based Medicine Module was funded by an educational
grant from Sanofi-Aventis Pharmaceuticals Education Center.
